{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:10:56Z","timestamp":1759191056001,"version":"3.44.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-01926-4","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:17:04Z","timestamp":1759151824000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative analysis of preoperative contrast-enhanced cone beam breast CT (CE-CBBCT) and MRI for differentiating pathological complete response from minimal residual disease in breast cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Yafei","family":"Wang","sequence":"first","affiliation":[]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[]},{"given":"Yue","family":"Ma","sequence":"additional","affiliation":[]},{"given":"Aidi","family":"Liu","sequence":"additional","affiliation":[]},{"given":"Mengran","family":"Zhao","sequence":"additional","affiliation":[]},{"given":"Keyi","family":"Bian","sequence":"additional","affiliation":[]},{"given":"Yueqiang","family":"Zhu","sequence":"additional","affiliation":[]},{"given":"Lu","family":"Yin","sequence":"additional","affiliation":[]},{"given":"Hong","family":"Lu","sequence":"additional","affiliation":[]},{"given":"Zhaoxiang","family":"Ye","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"issue":"7","key":"1926_CR1","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from national surgical adjuvant breast and bowel project B-18. J Clin Oncol. 1997;15(7):2483\u201393.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1926_CR2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","volume":"20","author":"WJ Gradishar","year":"2022","unstructured":"Gradishar WJ, Moran MS, Abraham J, et al. Breast cancer, version 3. 2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20(6):691\u2013722.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10","key":"1926_CR3","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.22.02571","volume":"41","author":"B Fisher","year":"2023","unstructured":"Fisher B, Bryant J, Mamounas E, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 2023;41(10):1795\u2013808.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1926_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-017-4598-5","volume":"168","author":"JH Volders","year":"2018","unstructured":"Volders JH, Negenborn VL, Spronk PE, et al. Breast-conserving surgery following neoadjuvant therapy-a systematic review on surgical outcomes. Breast Cancer Res Treat. 2018;168(1):1\u201312.","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"1926_CR5","doi-asserted-by":"publisher","first-page":"8060","DOI":"10.1245\/s10434-022-12300-x","volume":"29","author":"EA Elder","year":"2022","unstructured":"Elder EA, Livasy CA, Donahue EE, et al. Residual cancer burden class associated with survival outcomes in women with different phenotypic subtypes of breast cancer after neoadjuvant chemotherapy. Ann Surg Oncol. 2022;29(13):8060\u201369.","journal-title":"Ann Surg Oncol"},{"issue":"9938","key":"1926_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang LJ, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"28","key":"1926_CR7","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2017","unstructured":"Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2017;25(28):4414\u201322.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1926_CR8","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1634\/theoncologist.11-6-574","volume":"11","author":"I Sachelarie","year":"2006","unstructured":"Sachelarie I, Grossbard ML, Chadha M, et al. Primary systemic therapy of breast cancer. Oncologist. 2006;11(6):574\u201389.","journal-title":"Oncologist"},{"issue":"11","key":"1926_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1001\/jamasurg.2022.4118","volume":"157","author":"M Osdoit","year":"2022","unstructured":"Osdoit M, Yau C, Symmans WF, et al. Association of residual ductal carcinoma in situ with breast cancer recurrence in the Neoadjuvant I-SPY2 trial. JAMA Surg. 2022;157(11):1034\u201341.","journal-title":"JAMA Surg"},{"issue":"21","key":"1926_CR10","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1200\/JCO.2007.14.4899","volume":"26","author":"SC Hayes","year":"2008","unstructured":"Hayes SC, Janda M, Cornish B, et al. Lymphedema after breast cancer: incidence, risk factors, and effect on upper body function. J Clin Oncol. 2008;26(21):3536\u201342.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1926_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/pro6.1221","volume":"8","author":"T Kazuya","year":"2024","unstructured":"Kazuya T, Rei U, Takaya Y, et al. Lymphocytopenia following adjuvant radiotherapy for breast cancer. Precis Radiat OnCo. 2024;8(1):22\u201329.","journal-title":"Precis Radiat OnCo"},{"issue":"4","key":"1926_CR12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/SLA.0b013e3181c5dda3","volume":"251","author":"ME Straver","year":"2010","unstructured":"Straver ME, Loo CE, Rutgers EJT, et al. MRI-model to guide the surgical treatment in breast cancer patients after neoadjuvant chemotherapy. Ann Surg. 2010;251(4):701\u20137.","journal-title":"Ann Surg"},{"issue":"2","key":"1926_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejso.2006.09.019","volume":"33","author":"V Garimella","year":"2007","unstructured":"Garimella V, Qutob O, Fox JN, et al. Recurrence rates after MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. Eur J Surg Oncol. 2007;33(2):157\u201361.","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"1926_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.clbc.2016.12.010","volume":"17","author":"YL Gu","year":"2017","unstructured":"Gu YL, Pan SM, Ren J, Ren J, et al. Role of magnetic resonance imaging in detection of pathologic complete remission in breast cancer patients treated with neoadjuvant chemotherapy: a meta-analysis. Clin Breast Cancer. 2017;17(4):245\u201355.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"1926_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41523-022-00475-1","volume":"8","author":"LM Janssen","year":"2022","unstructured":"Janssen LM, Dekker BM, Gilhuijs KGA, et al. MRI to assess response after neoadjuvant chemotherapy in breast cancer subtypes: a systematic review and meta-analysis. NPJ Breast Cancer. 2022;8(1):107.","journal-title":"NPJ Breast Cancer"},{"issue":"7","key":"1926_CR16","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1007\/s00330-017-5251-8","volume":"28","author":"SY Kim","year":"2018","unstructured":"Kim SY, Cho N, Shin SU, et al. Contrast-enhanced MRI after neoadjuvant chemotherapy of breast cancer: Lesion-to-background parenchymal signal enhancement ratio for discriminating pathological complete response from minimal residual tumour. Eur Radiol. 2018;28(7):2986\u201395.","journal-title":"Eur Radiol"},{"issue":"4","key":"1926_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/pro6.1245","volume":"8","author":"J Qin","year":"2024","unstructured":"Qin J, Zhao J, Yu J, et al. PET\/CT downgraded the staging of a breast cancer patient and changed their treatment management. Precis Radiat Oncol. 2024, 18F]-NOTA-FAPI-04 8(4):227\u201331.","journal-title":"Precis Radiat Oncol"},{"issue":"1","key":"1926_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.ejrad.2014.05.032","volume":"84","author":"BH Zhao","year":"2015","unstructured":"Zhao BH, Zhang XH, Cai WX, Conover D, Ning R. Cone beam breast CT with multiplanar and three-dimensional visualization in differentiating breast masses compared with mammography. Eur J Radiol. 2015;84(1):48\u201353.","journal-title":"Eur J Radiol"},{"issue":"3","key":"1926_CR19","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00330-021-08179-z","volume":"32","author":"YQ Zhu","year":"2022","unstructured":"Zhu YQ, O\u2019Connell AM, Ma Y, et al. Dedicated breast CT: State of the art-part I. Historical evolution and technical aspects. Eur Radiol. 2022;32(3):1579\u201389.","journal-title":"Eur Radiol"},{"key":"1926_CR20","first-page":"64","volume":"4","author":"S Vedantham","year":"2014","unstructured":"Vedantham S, O\u2019Connell AM, Shi LX, et al. Dedicated breast CT: feasibility for monitoring neoadjuvant chemotherapy treatment. J Clin Imag Sci. 2014;4:64.","journal-title":"J Clin Imag Sci"},{"key":"1926_CR21","doi-asserted-by":"crossref","unstructured":"Chen S, Li S, Zhou CY, et al. Assessment of cone-beam breast computed tomography for predicting pathologic response to neoadjuvant chemotherapy in breast cancer: a prospective study. J Oncol. 2022;9321763.","DOI":"10.1155\/2022\/9321763"},{"issue":"9","key":"1926_CR22","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.acra.2022.12.027","volume":"30","author":"YF Wang","year":"2023","unstructured":"Wang YF, Zhao MR, Ma Y, et al. Accuracy of preoperative contrast-enhanced cone beam breast CT in assessment of residual tumor after neoadjuvant chemotherapy: a comparative study with breast MRI. Acad Radiol. 2023;30(9):1805\u201315.","journal-title":"Acad Radiol"},{"issue":"8","key":"1926_CR23","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1007\/s00330-023-09547-7","volume":"33","author":"RAW Ploumen","year":"2023","unstructured":"Ploumen RAW, Mooij CMD, Gommers S, et al. Imaging findings for response evaluation of ductal carcinoma in situ in breast cancer patients treated with neoadjuvant systemic therapy: a systematic review and meta-analysis. Eur Radiol. 2023;33(8):5423\u201335.","journal-title":"Eur Radiol"},{"key":"1926_CR24","unstructured":"D\u2019Orsi C, Sickles EA, Mendelson EB. Morris EA ACR BI-RADS atlas, breast imaging reporting and data system. 2013. American College of Radiology, Reston."},{"issue":"10","key":"1926_CR25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1055\/s-2007-1022338","volume":"54","author":"HP Sinn","year":"1994","unstructured":"Sinn HP, Schmid H, Junkermann H, Kaufmann M. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe FrauenheilkD. 1994;54(10):552\u20138.","journal-title":"Geburtshilfe FrauenheilkD"},{"key":"1926_CR26","volume-title":"Of the AJCC cancer staging manual. AJCC cancer staging manual","author":"SB Edge","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, et al. Breast cancer staging: the. In: of the AJCC cancer staging manual. AJCC cancer staging manual. 7th. New York: Springer; 2010.","edition":"7th"},{"issue":"8","key":"1926_CR27","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","volume":"26","author":"AS Coates","year":"2015","unstructured":"Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies-improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol. 2015;26(8):1533\u201346.","journal-title":"Ann Oncol"},{"issue":"2","key":"1926_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","volume":"86","author":"PE Shrout","year":"1979","unstructured":"Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420\u20138.","journal-title":"Psychol Bull"},{"issue":"3","key":"1926_CR29","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1177\/02841851221112562","volume":"64","author":"AD Liu","year":"2023","unstructured":"Liu AD, Ma Y, Yin L, et al. Comparison of malignant calcification identification between breast cone-beam computed tomography and digital mammography. Acta Radiol. 2023;64(3):962\u201370.","journal-title":"Acta Radiol"},{"issue":"6","key":"1926_CR30","doi-asserted-by":"publisher","first-page":"884","DOI":"10.2214\/AJR.22.27756","volume":"219","author":"D Bernardi","year":"2022","unstructured":"Bernardi D, Vatteroni G, Acquaviva A, et al. Contrast-enhanced mammography versus MRI in the evaluation of neoadjuvant therapy response in patients with breast cancer: a prospective study. AJR Am J roentgenol. 2022;219(6):884\u2013994.","journal-title":"AJR Am J roentgenol"},{"issue":"1","key":"1926_CR31","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13058-017-0899-1","volume":"19","author":"V Iotti","year":"2017","unstructured":"Iotti V, Ravaioli S, Vacondio R, et al. Contrast-enhanced spectral mammography in neoadjuvant chemotherapy monitoring: a comparison with breast magnetic resonance imaging. Breast Cancer Res. 2017;19(1):106.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1926_CR32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1097\/SLA.0b013e3182686bd9","volume":"257","author":"HG Moon","year":"2013","unstructured":"Moon HG, Han W, Ahn SK, et al. Breast cancer molecular phenotype and the use of HER2-targeted agents influence the accuracy of breast MRI after neoadjuvant chemotherapy. Ann Surg. 2013;257(1):133\u20137.","journal-title":"Ann Surg"},{"issue":"3","key":"1926_CR33","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1148\/radiol.2015150006","volume":"277","author":"S Schrading","year":"2015","unstructured":"Schrading S, Kuhl CK. Breast cancer: influence of taxanes on response assessment with dynamic contrast-enhanced MR Imaging. Radiology. 2015;277(3):687\u201396.","journal-title":"Radiology"},{"issue":"4","key":"1926_CR34","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1007\/s00330-020-07277-8","volume":"31","author":"Y Ma","year":"2021","unstructured":"Ma Y, Liu A, O\u2019Connell AM, et al. Contrast-enhanced cone beam breast CT features of breast cancers: correlation with immunohistochemical receptors and molecular subtypes. Eur Radiol. 2021;31(4):2580\u20139.","journal-title":"Eur Radiol"},{"issue":"6","key":"1926_CR35","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1200\/JCO.2010.31.1258","volume":"29","author":"CE Loo","year":"2011","unstructured":"Loo CE, Straver ME, Rodenhuis S, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol. 2011;29(6):660\u20136.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1926_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13058-024-01781-1","volume":"26","author":"MF Wang","year":"2024","unstructured":"Wang MF, Du SY, Gao S, et al. MRI-based tumor shrinkage patterns after early neoadjuvant therapy in breast cancer: correlation with molecular subtypes and pathological response after therapy. Breast Cancer Res. 2024;26(1):26.","journal-title":"Breast Cancer Res"},{"key":"1926_CR37","doi-asserted-by":"publisher","first-page":"101965","DOI":"10.1016\/j.ctrv.2020.101965","volume":"84","author":"F Schettini","year":"2020","unstructured":"Schettini F, Pascual T, Conte B, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis. Cancer Treat Rev. 2020;84:101965.","journal-title":"Cancer Treat Rev"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01926-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01926-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01926-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T13:17:07Z","timestamp":1759151827000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01926-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1926"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01926-4","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the institutional review board at Tianjin Medical University Cancer Institute & Hospital (bc2019048), and was performed in accordance with the Declaration of Helsinki. Written informed consents were obtained from all patients prior to CE-CBBCT examinations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"390"}}